Skip to main content

15.04.2024 | Original Research Article

Development of Patient and Caregiver Conceptual Models Investigating the Health-Related Quality of Life Impacts of Malignant Pleural Mesothelioma

verfasst von: Adam E. J. Gibson, Waqas Ahmed, Louise Longworth, Bryan Bennett, Melinda Daumont, Liz Darlison

Erschienen in: The Patient - Patient-Centered Outcomes Research

Einloggen, um Zugang zu erhalten

Abstract

Background

Malignant pleural mesothelioma (MPM) is a rare and usually fatal malignancy frequently linked to occupational asbestos exposures and associated with poor prognosis and considerable humanistic burden. The study aimed to develop conceptual models of the health-related quality of life (HRQoL) impact on patients with and receiving treatment for MPM, and the burden on their caregivers.

Methods

This multi-country study (Australia and United Kingdom) adopted a qualitative methodology to conduct semi-structured, independent interviews with people with MPM (n = 26), current caregivers (n = 20), and caregivers of people who had recently died because of MPM (n = 4). Participants were recruited using a purposive sampling approach and interviews conducted via telephone between January 2021 and January 2022. Transcripts were analysed using thematic analysis and used to construct conceptual models.

Results

Patient analysis yielded four overarching themes: (1) debilitating burden of breathlessness and fatigue; (2) physical mesothelioma symptoms experienced by patients; (3) distress of MPM on the self and family; and (4) treatment is worth ‘having a go’ despite the potential impact on symptoms. Caregiver analysis yielded five core themes: (1) daily life limited by caregiving duties; (2) emotional well-being and the need for support; (3) the relational role shift to caregiver; (4) time spent providing care negatively impacts work and productivity; and (5) positive aspects and outcomes of caregiving.

Conclusions

This study highlights the substantial daily and emotional HRQoL impact that MPM symptoms have on patients and caregivers. Both groups reduced work, productivity, and social and leisure activities. There was evidence of positive HRQoL impacts as a result of immunotherapy and radiotherapy, but less for chemotherapy. Caregiver impacts were intensified during the end-of-life period and persisted following patient death. Evident is a need for increased psychological support, information, and advice for caregivers, increased during the end-of-life period.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Hamra G, Loomis D, Dement J. Examining the association of lung cancer and highly correlated fibre size-specific asbestos exposures with a hierarchical Bayesian model. Occup Environ Med. 2014;71:353–7.CrossRefPubMed Hamra G, Loomis D, Dement J. Examining the association of lung cancer and highly correlated fibre size-specific asbestos exposures with a hierarchical Bayesian model. Occup Environ Med. 2014;71:353–7.CrossRefPubMed
2.
Zurück zum Zitat Røe OD, Stella GM. Malignant pleural mesothelioma: history, controversy, and future of a man-made epidemic. Eur Respir Rev. 2017;24:115–31.CrossRef Røe OD, Stella GM. Malignant pleural mesothelioma: history, controversy, and future of a man-made epidemic. Eur Respir Rev. 2017;24:115–31.CrossRef
3.
Zurück zum Zitat Van Zandwijk N, Clarke, C., Henderson, D., Musk, W., Fong, K, Penman, A. Guidelines for the diagnosis and treatment of malignant pleural mesothelioma. J Thorac Dis. 2013;5(6):E254-E307. Van Zandwijk N, Clarke, C., Henderson, D., Musk, W., Fong, K, Penman, A. Guidelines for the diagnosis and treatment of malignant pleural mesothelioma. J Thorac Dis. 2013;5(6):E254-E307.
4.
Zurück zum Zitat Ettinger D. NCCN guidelines insights: malignant pleural mesothelioma, version 3.2016. Off J Natl Comprehen Cancer Netw. 2016;14(7):825-36. Ettinger D. NCCN guidelines insights: malignant pleural mesothelioma, version 3.2016. Off J Natl Comprehen Cancer Netw. 2016;14(7):825-36.
5.
Zurück zum Zitat Cavone D, Caputi A, De Maria L, Cannone ESS, Mansi F, Vimercati L. Epidemiology of mesothelioma. Environments 2019;6(7):76. Cavone D, Caputi A, De Maria L, Cannone ESS, Mansi F, Vimercati L. Epidemiology of mesothelioma. Environments 2019;6(7):76.
6.
Zurück zum Zitat Bianchi C, Bianchi T. Global mesothelioma epidemic: trend and features. Indian J Occupat Environ Med. 2014;18(2):82-8. Bianchi C, Bianchi T. Global mesothelioma epidemic: trend and features. Indian J Occupat Environ Med. 2014;18(2):82-8.
8.
Zurück zum Zitat Musk ABW, de Klerk N, Brims FJ. Mesothelioma in Australia: a review. Med J Aust. 2017;207(10):449–52.CrossRefPubMed Musk ABW, de Klerk N, Brims FJ. Mesothelioma in Australia: a review. Med J Aust. 2017;207(10):449–52.CrossRefPubMed
9.
Zurück zum Zitat Shah N, Williams, A. Surviving the asbestos epidemic. Insurance Digest (European). 2001:14-8. Shah N, Williams, A. Surviving the asbestos epidemic. Insurance Digest (European). 2001:14-8.
11.
Zurück zum Zitat Baas P, Scherpereel A, Nowak AK, Fujimoto N, Peters S, Zalcman G. First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial. The Lancet. 2021;397(10272):375-86. Baas P, Scherpereel A, Nowak AK, Fujimoto N, Peters S, Zalcman G. First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial. The Lancet. 2021;397(10272):375-86.
12.
Zurück zum Zitat Nakajima E, Vellanki, J., Larkins, E., Chatterjee, Mishra-Kalyani, PS, Donoghue, M. FDA approval summary: nivolumab in combination with ipilimumab for the treatment of unresectable malignant pleural mesothelioma. Clin Cancer Res. 2022;28(3):446-51. Nakajima E, Vellanki, J., Larkins, E., Chatterjee, Mishra-Kalyani, PS, Donoghue, M. FDA approval summary: nivolumab in combination with ipilimumab for the treatment of unresectable malignant pleural mesothelioma. Clin Cancer Res. 2022;28(3):446-51.
13.
Zurück zum Zitat EMA. Assessment report: ipilimumab/nivolumab (EMA/CHMP/260350/2021). EMA; 2021:1–164. EMA. Assessment report: ipilimumab/nivolumab (EMA/CHMP/260350/2021). EMA; 2021:1–164.
14.
Zurück zum Zitat PBS. Submission: nivolumab plus ipilimumab. Retrieved from: https://wwwpbsgovau/industry/listing/elements/pbac-meetings/psd/2021-03/files/nivolumab-plus-ipilimumab-psd-mar-2021docx. 24th June 2022. 2021:1-42. PBS. Submission: nivolumab plus ipilimumab. Retrieved from: https://​wwwpbsgovau/​industry/​listing/​elements/​pbac-meetings/​psd/​2021-03/​files/​nivolumab-plus-ipilimumab-psd-mar-2021docx.​ 24th June 2022. 2021:1-42.
15.
Zurück zum Zitat Kondola S, Manners D, Nowak AK. Malignant pleural mesothelioma: an update on diagnosis and treatment options. Ther Adv Respir Dis. 2016;10(3):275–88.CrossRefPubMedPubMedCentral Kondola S, Manners D, Nowak AK. Malignant pleural mesothelioma: an update on diagnosis and treatment options. Ther Adv Respir Dis. 2016;10(3):275–88.CrossRefPubMedPubMedCentral
16.
Zurück zum Zitat Girgis S, Smith AB, Lamber S, Waller A, Girgis A. ‘It sort of hit me like a baseball bat between the eyes’: a qualitative study of the psychosocial experiences of mesothelioma patients and carers. Support Care Cancer. 2019;27(2):631–8.CrossRefPubMed Girgis S, Smith AB, Lamber S, Waller A, Girgis A. ‘It sort of hit me like a baseball bat between the eyes’: a qualitative study of the psychosocial experiences of mesothelioma patients and carers. Support Care Cancer. 2019;27(2):631–8.CrossRefPubMed
17.
Zurück zum Zitat Sturges J, Hanrahan KJ. Comparing telephone and face-to-face qualitative interviewing: a research note. Qual Res. 2004;4(1):107–18.CrossRef Sturges J, Hanrahan KJ. Comparing telephone and face-to-face qualitative interviewing: a research note. Qual Res. 2004;4(1):107–18.CrossRef
19.
Zurück zum Zitat Clarke V, Braun, V. Thematic analysis. In: Michalos AC (ed) Encyclopaedia of quality of life and well-being research. Springer, Dordrecht. 2014. Clarke V, Braun, V. Thematic analysis. In: Michalos AC (ed) Encyclopaedia of quality of life and well-being research. Springer, Dordrecht. 2014.
20.
Zurück zum Zitat Coast J. Qualitative methods for health economics: rowan and littlefield international; 2017. Coast J. Qualitative methods for health economics: rowan and littlefield international; 2017.
21.
Zurück zum Zitat Silverman D. Doing qualitative research: a practical handbook. London: SAGE; 2010. Silverman D. Doing qualitative research: a practical handbook. London: SAGE; 2010.
22.
Zurück zum Zitat Guest G, Bunce A, Johnson L. An experiment with data saturation and variability. Field Methods. 2006;18(1):59–82.CrossRef Guest G, Bunce A, Johnson L. An experiment with data saturation and variability. Field Methods. 2006;18(1):59–82.CrossRef
23.
Zurück zum Zitat Moore S, Darlison L, Tod AM. Living with mesothelioma: a literture review European. J Cancer Care. 2010;19:458–68.CrossRef Moore S, Darlison L, Tod AM. Living with mesothelioma: a literture review European. J Cancer Care. 2010;19:458–68.CrossRef
24.
Zurück zum Zitat Brims F, Gunatilake, S., Lawrie, I., Marshall, L., Fogg, C, Chauhan, AJ. Early specialist palliative care on quality of life for malignant pleural mesothelioma: a randomised controlled trial. Thorax. 2019;74:354-61. Brims F, Gunatilake, S., Lawrie, I., Marshall, L., Fogg, C, Chauhan, AJ. Early specialist palliative care on quality of life for malignant pleural mesothelioma: a randomised controlled trial. Thorax. 2019;74:354-61.
25.
Zurück zum Zitat Arber A, Spener L. ‘It’s all bad news’: the first 3 months following a diagnosis of malignant pleural mesothelioma. Psychooncology. 2013;22(7):1528–33.CrossRefPubMed Arber A, Spener L. ‘It’s all bad news’: the first 3 months following a diagnosis of malignant pleural mesothelioma. Psychooncology. 2013;22(7):1528–33.CrossRefPubMed
26.
Zurück zum Zitat Hughes N, Arber A. The lived eperience of patients with pleural mesothelioma. Int J Palliat Nurs. 2009;14(2):66–71.CrossRef Hughes N, Arber A. The lived eperience of patients with pleural mesothelioma. Int J Palliat Nurs. 2009;14(2):66–71.CrossRef
27.
Zurück zum Zitat Ejegi-Memeg S, Sherborne, V., Harrison, M., Taylor, B., Senek, M, Gardiner, C. Patients’ and informal carers’ experience of living with mesothelioma: a systematic rapid review and synthesis of the literature. Eur J Oncol Nurs. 2022;58:102122. Ejegi-Memeg S, Sherborne, V., Harrison, M., Taylor, B., Senek, M, Gardiner, C. Patients’ and informal carers’ experience of living with mesothelioma: a systematic rapid review and synthesis of the literature. Eur J Oncol Nurs. 2022;58:102122.
28.
Zurück zum Zitat Harrison M, Gardiner C, Taylor B, Ejegi-Memeh S, Darlison L. Understanding the palliative care needs and experiences of people with mesothelioma and their family carers: an integrative systematic review. Palliat Med. 2021;35(6):1039–51.CrossRefPubMedPubMedCentral Harrison M, Gardiner C, Taylor B, Ejegi-Memeh S, Darlison L. Understanding the palliative care needs and experiences of people with mesothelioma and their family carers: an integrative systematic review. Palliat Med. 2021;35(6):1039–51.CrossRefPubMedPubMedCentral
29.
Zurück zum Zitat Warby A, Dhillon HM, Kao S, Vardy JL. A survey of patient and caregiver experience with malignant pleural mesothelioma. Support Care Cancer. 2019;27:4675–86.CrossRefPubMed Warby A, Dhillon HM, Kao S, Vardy JL. A survey of patient and caregiver experience with malignant pleural mesothelioma. Support Care Cancer. 2019;27:4675–86.CrossRefPubMed
30.
Zurück zum Zitat Henson K, Wickramasinghe B, Pitman A. Risk of suicide after cancer diagnosis in England. JAMA Psychiatry. 2019;76(1):51–60.CrossRefPubMed Henson K, Wickramasinghe B, Pitman A. Risk of suicide after cancer diagnosis in England. JAMA Psychiatry. 2019;76(1):51–60.CrossRefPubMed
Metadaten
Titel
Development of Patient and Caregiver Conceptual Models Investigating the Health-Related Quality of Life Impacts of Malignant Pleural Mesothelioma
verfasst von
Adam E. J. Gibson
Waqas Ahmed
Louise Longworth
Bryan Bennett
Melinda Daumont
Liz Darlison
Publikationsdatum
15.04.2024
Verlag
Springer International Publishing
Erschienen in
The Patient - Patient-Centered Outcomes Research
Print ISSN: 1178-1653
Elektronische ISSN: 1178-1661
DOI
https://doi.org/10.1007/s40271-024-00690-x